CompletedNot Applicable

Rapid On-site Cytopathologic Evaluation in the Diagnosis of Hilar/Mediastinal Adenopathy

Italy164 participantsStarted 2009-05

Plain-language summary

The purpose of this study is to determine whether rapid on-site cytopathologic evaluation (ROSE) can increase the diagnostic yield of transbronchial needle aspiration (TBNA) in the diagnosis of hilar and mediastinal lymphadenopathy.

Who can participate

Age range18 Years – 90 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * 18 years old and older * Hilar and/or mediastinal lymphadenopathy (\> 1 cm on the short axis, as assessed by contrast-enhanced CT scan (computed tomography)) Exclusion Criteria: * Uncontrolled coagulopathy * Refusal to sign informed consent

What they're measuring

Examine the diagnostic yield of the TBNA with ROSE arm versus the diagnostic yield of TBNA alone arm

Timeframe: 6-12 months

Trial details

NCT IDNCT00915330

SponsorMaggiore Bellaria Hospital, Bologna

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2010-02

View on ClinicalTrials.gov More Lung Cancer trials